Ridgeback Biotherapeutics | search
Click here to view Ridgeback Biotherapeutics news from 60+ newspapers.
Bookmark or Share- Lagevrio (molnupiravir) - Ridgeback BiotherapeuticsLagevrio (molnupiravir) is a direct-acting oral, broad-spectrum antiviral agent in clinical development as a treatment for COVID-19. Ridgeback has completed Phase 1 and Phase 2 studies. The program has advanced into Phase 3 development as a therapeutic for COVID-19 and Lagevrio was found to significantly reduce the risk of hospitalization or ...
- Ridgeback BiotherapeuticsRidgeback Biotherapeutics develops potential medications to treat infectious diseases that have limited or no treatment options, like Ebola and COVID-19. Our Difference : We commit resources and expertise for poorly-understood diseases.
- Ridgeback Biotherapeutics and Merck Announce Preliminary Findings from ...Headquartered in Miami, Florida, Ridgeback Biotherapeutics LP is a biotechnology company focused on emerging infectious diseases. Ridgeback markets EbangaTM for the treatment of Ebola and has a late-stage development pipeline which includes molnupiravir for the treatment of COVID-19.
- Pipeline - Ridgeback BiotherapeuticsAt Ridgeback Biotherapeutics, our mission is clear – serve the patient by developing important innovations as efficiently as possible. FDA-Approved Biologic: Several hundred patients have received our Ebola therapeutic free of charge, including post-FDA approval.
- Merck and Ridgeback Biotherapeutics Announce Initiation of Pivotal ...Headquartered in Miami, Florida, Ridgeback Biotherapeutics LP is a biotechnology company focused on emerging infectious diseases. Ridgeback markets Ebanga TM for the treatment of Ebola and has a late-stage development pipeline which includes molnupiravir for the treatment of COVID-19.
More
